{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:30:29Z","timestamp":1780511429558,"version":"3.54.1"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Levamisole is an anthelminthic that was first used as a de-worming agent in humans and animals. It has also been used to treat inflammatory conditions as well as certain types of cancer. Levamisole was discontinued for human use in the early 21st century due to toxic side effects including agranulocytosis and vasculitis. Recently, levamisole was discovered as a cocaine adulterant after reports emerged of drug users with the above disorders. As the prevalence of cocaine usage has grown in the last 15 years, measurement of levamisole in human samples has become increasingly important. This review focuses on the various bioanalytical methods available for the determination of levamisole in human plasma and urine. Earlier methods employed gas chromatography coupled with nitrogen-selective thermionic specific detection and nitrogen-phosphorus detection, as well as high performance liquid chromatography coupled with ultraviolet detection. In addition, gas chromatography-mass spectrometry (GC-MS) and high performance liquid chromatography-tandem mass spectrometry (LC-MS\/MS) have also been described. Currently, GC-MS appears to be the method of choice however recent developments in the area of LC-MS\/MS make this technology an attractive alternative. The merits of both GC-MS and LC-MS\/MS for the determination of levamisole are evaluated on the basis of sample preparation, chromatographic separation conditions, run time, and analytical performance. In addition, emerging methods in this area are also reviewed.<\/jats:p>","DOI":"10.1515\/cclm-2012-0519","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T12:40:54Z","timestamp":1352378454000},"page":"205-212","source":"Crossref","is-referenced-by-count":28,"title":["Bioanalytical methods for quantitation of levamisole, a widespread cocaine adulterant"],"prefix":"10.1515","volume":"51","author":[{"given":"Jennifer L.","family":"Shea","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto , ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2012,11,8]]},"reference":[{"key":"2022011514475694109_j_cclm-2012-0519_ref_001","doi-asserted-by":"crossref","unstructured":"Thienpont D, Vanparijs OF, Raeymaekers AH, Vandenberk J, Demoen PJ, Allewijn FT, et al. Tetramisole (R 8299), a new, potent broad spectrum anthelmintic. Nature 1966;209:1084\u20136.","DOI":"10.1038\/2091084a0"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_002","doi-asserted-by":"crossref","unstructured":"Amery WK, Bruynseels JP. Levamisole, the story and the lessons. Int J Immunopharmacol 1992;14:481\u20136.10.1016\/0192-0561(92)90179-O1618599","DOI":"10.1016\/0192-0561(92)90179-O"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_003","doi-asserted-by":"crossref","unstructured":"Taal BG, Van Tinteren H, Zoetmulder FA; NACCP group. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001;85:1437\u201343.10.1054\/bjoc.2001.2117","DOI":"10.1054\/bjoc.2001.2117"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_004","doi-asserted-by":"crossref","unstructured":"Rosenthal M, Trabert U, Muller W. Letter: leucocytotoxic effect of levamisole. Lancet 1976;i:369.54782","DOI":"10.1016\/S0140-6736(76)90133-1"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_005","doi-asserted-by":"crossref","unstructured":"Graber H, Takacs L, Vedrody K. Agranulocytosis due to levamisole. Lancet 1976;ii:1248.","DOI":"10.1016\/S0140-6736(76)91177-6"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_006","doi-asserted-by":"crossref","unstructured":"Ruuskanen O, Remes M, Makela AL, Isomaki H, Toivanen A. Levamisole and agranulocytosis. Lancet 1976;2:958\u20139.6218010.1016\/S0140-6736(76)90916-8","DOI":"10.1016\/S0140-6736(76)90916-8"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_007","doi-asserted-by":"crossref","unstructured":"Macfarlane DG, Bacon PA. Levamisole-induced vasculitis due to circulating immune complexes. Br Med J 1978;1:407\u20138.14653410.1136\/bmj.1.6110.407","DOI":"10.1136\/bmj.1.6110.407"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_008","doi-asserted-by":"crossref","unstructured":"Scheinberg MA, Bezerra JB, Almeida FA, Silveira LA. Cutaneous necrotising vasculitis induced by levamisole. Br Med J 1978;1:408.10.1136\/bmj.1.6110.408624030","DOI":"10.1136\/bmj.1.6110.408"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_009","doi-asserted-by":"crossref","unstructured":"Hook CC, Kimmel DW, Kvols LK, Scheithauer BW, Forsyth PA, Rubin J, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992;31:262\u20137.10.1002\/ana.4103103061637134","DOI":"10.1002\/ana.410310306"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_010","doi-asserted-by":"crossref","unstructured":"Menni S, Pistritto G, Gianotti R, Ghio L, Edefonti A. Ear lobe bilateral necrosis by levamisole-induced occlusive vasculitis in a pediatric patient. Pediatr Dermatol 1997;14:477\u20139.10.1111\/j.1525-1470.1997.tb00695.x","DOI":"10.1111\/j.1525-1470.1997.tb00695.x"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_011","doi-asserted-by":"crossref","unstructured":"Kouassi E, Caill\u00e9 G, L\u00e9ry L, Larivi\u00e8re L, V\u00e9zina M. Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. Biopharm Drug Dispos 1986;7:71\u201389.10.1002\/bdd.2510070110","DOI":"10.1002\/bdd.2510070110"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_012","doi-asserted-by":"crossref","unstructured":"Reid JM, Kovach JS, O\u2019Connell MJ, Bagniewski PG, Moertel CG. Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer. Cancer Chemother Pharmacol 1998;41:477\u201384.10.1007\/s002800050770","DOI":"10.1007\/s002800050770"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_013","unstructured":"Adams JG. Pharmacokinetics of levamisole. J Rheum 1978;5:137\u201342."},{"key":"2022011514475694109_j_cclm-2012-0519_ref_014","doi-asserted-by":"crossref","unstructured":"Ho EN, Leung DK, Leung GN, Wan TS, Wong AS, Wong CH, et al. Aminorex and rexamino as metabolites of levamisole in the horse. Anal Chim Acta 2009;638:58\u201368.http:\/\/gateway.webofknowledge.com\/gateway\/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000264898500008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3","DOI":"10.1016\/j.aca.2009.02.033"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_015","doi-asserted-by":"crossref","unstructured":"Barker SA. The formation of aminorex in racehorses following levamisole administration. A quantitative and chiral analysis following synthetic aminorex or levamisole administration vs. aminorex-positive samples from the field: a preliminary report. J Vet Pharm Ther 2008;32:160\u20136.http:\/\/gateway.webofknowledge.com\/gateway\/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000263966800008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3","DOI":"10.1111\/j.1365-2885.2008.01015.x"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_016","unstructured":"Bertol E, Mari F, Milia MG, Politi L, Furlanetto S, Karch SB. Determination of aminorex in human urine samples by GC-MS after use of levamisole. J Pharm Biomed Anal 2011;55: 1186\u20139.http:\/\/gateway.webofknowledge.com\/gateway\/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000291129700042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016\/j.jpba.2011.03.03921531521"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_017","unstructured":"Valentino AM, Fuentecilla K. Levamisole: an analytical profile. Microgram J 2005;3:134\u20137."},{"key":"2022011514475694109_j_cclm-2012-0519_ref_018","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2011. New York: United Nations Publication, 2011."},{"key":"2022011514475694109_j_cclm-2012-0519_ref_019","doi-asserted-by":"crossref","unstructured":"Zhu NY, LeGatt DF, Turner AR. Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med 2009;150:287\u20139.","DOI":"10.7326\/0003-4819-150-4-200902170-00102"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_020","doi-asserted-by":"crossref","unstructured":"Raymon LP, Isenschmid DS. The possible role of levamisole in illicit cocaine preparations. J Anal Toxicol 2009;33:620\u20132.http:\/\/gateway.webofknowledge.com\/gateway\/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000272150000008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f32004013810.1093\/jat\/33.9.620","DOI":"10.1093\/jat\/33.9.620"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_021","doi-asserted-by":"crossref","unstructured":"Woestenborghs R, Michielsen L, Heykants J. Determination of levamisole in plasma and animal tissues by gas chromatography with thermionic detection. J Chromatog 1981;224:25\u201332.","DOI":"10.1016\/S0378-4347(00)80134-6"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_022","doi-asserted-by":"crossref","unstructured":"Marriner S, Galbraith EA, Bogan JA. Determination of the anthelmintic levamisole in plasma and gastro-intestinal fluids by high-performance liquid chromatography. Analyst 1980;150:993\u20136.","DOI":"10.1039\/an9800500993"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_023","doi-asserted-by":"crossref","unstructured":"Vandamme TF, Demoustier M, Rollmann B. Quantitation of levamisole in plasma using high performance liquid chromatography. Eur J Drug Metab Pharmacokinet 1995;20:145\u20139.10.1007\/BF032263698582440","DOI":"10.1007\/BF03226369"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_024","doi-asserted-by":"crossref","unstructured":"Buchanan JA, Heard K, Burbach C, Wilson ML, Dart R. Prevalence of levamisole in urine toxicology screens positive for cocaine in an inner-city hospital. J Am Med Assoc 2011;305:1657\u20138.","DOI":"10.1001\/jama.2011.531"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_025","unstructured":"Centers for Disease Control and Prevention (CDC). Agranulocytosis associated with cocaine use \u2013 four States, March 2008-November 2009. MMWR Morb Mortal Wkly Rep 2009;58:1381\u20135."},{"key":"2022011514475694109_j_cclm-2012-0519_ref_026","doi-asserted-by":"crossref","unstructured":"Tran H, Tan D, Marnejon TP. Cutaneous vasculopathy associated with levamisole-adulterated cocaine. Clin Med Res 2012 Jul 9. doi:10.3121\/cmr.2012.1085.10.3121\/cmr.2012.1085","DOI":"10.3121\/cmr.2012.1085"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_027","doi-asserted-by":"crossref","unstructured":"Trehy ML, Brown DJ, Woodruff JT, Westenberger BJ, Nychis WG, Reuter N, et al. Determination of levamisole in urine by gas chromatography-mass spectrometry. J Anal Toxicol 2011;35:545\u201350.2200467310.1093\/anatox\/35.8.545","DOI":"10.1093\/anatox\/35.8.545"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_028","doi-asserted-by":"crossref","unstructured":"Lynch KL, Dominy SS, Graf J, Kral AH. Detectiojn of levamisole exposure in cocaine users by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2011;35:176\u20138.2143915410.1093\/anatox\/35.3.176","DOI":"10.1093\/anatox\/35.3.176"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_029","doi-asserted-by":"crossref","unstructured":"Tong L, Ding L, Li Y, Wang Z, Wang J, Liu Y, et al. A sensitive LC-MS\/MS method for determination of levamisole in human plasma: application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:299\u2013303.","DOI":"10.1016\/j.jchromb.2010.11.015"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_030","unstructured":"Dowling G, Regan L. A new mixed mode solid phase extraction strategy for opiods, cocaines, amphetamines and adulterants in human blood with hybrid liquid chromatography tandem mass spectrometry detection. J Pharm Biomed Anal 2011;54:1136\u201345.http:\/\/gateway.webofknowledge.com\/gateway\/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000286952100028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016\/j.jpba.2010.11.043"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_031","doi-asserted-by":"crossref","unstructured":"Islam MD, Haberhauer G, Gerzabek M, Cannavan A. Liquid chromatography-tandem mass spectrometry method for the determination of anthelmintics in alfalfa plants. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2012;29:1679\u201388.10.1080\/19440049.2012.702320","DOI":"10.1080\/19440049.2012.702320"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_032","doi-asserted-by":"crossref","unstructured":"Lopes RP, Reyes RC, Romero-Gonz\u00e1lez R, Vidal JL, Frenich AG. Multiresidue determination of veterinary drugs in aquaculture fish samples by ultra high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2012;895\u2013896:39\u201347.","DOI":"10.1016\/j.jchromb.2012.03.011"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_033","doi-asserted-by":"crossref","unstructured":"Gallo P, Fabbrocino S, Serpe L. Determination of levamisole in feeds by liquid chromatography coupled to electrospray mass spectrometry on an ion trap. Rapid Commun Mass Spectrom 2012;26:733\u20139.22368052","DOI":"10.1002\/rcm.6154"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_034","doi-asserted-by":"crossref","unstructured":"Hall AB, Coy SL, Nazarov EG, Vouros P. Rapid separation and characterization of cocaine and cocaine cutting agents by differential mobility spectrometry-mass spectrometry. J Forensic Sci 2012;57:750\u20136.10.1111\/j.1556-4029.2011.02033.xhttp:\/\/gateway.webofknowledge.com\/gateway\/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000302999000027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f322235847","DOI":"10.1111\/j.1556-4029.2011.02033.x"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_035","doi-asserted-by":"crossref","unstructured":"Casale JF, Colley VL, LeGatt DF. Determination of phenyltetrahydroimidazothiazole enantioners (levamisole\/dexamisole) in illicit cocaine seizures and in the urine of cocaine abusers via chiral capillary gas chromatography \u2013 flame-ionization detection: clinical and forensic perspectives. J Anal Toxicol 2012;36:130\u20135.","DOI":"10.1093\/jat\/bkr025"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_036","doi-asserted-by":"crossref","unstructured":"Janssen PA. The levamisole story. Prog Drug Res 1976;20: 347\u201383.827785","DOI":"10.1007\/978-3-0348-7094-8_11"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_037","doi-asserted-by":"crossref","unstructured":"Bullock MW, Hand JJ, Waletzky E. Resolution and racemisation of dl-tetramisole, dl-6-phenyl-2,3,5,6-tetrahydroimidazo-[2,1-b]thiazole. J Med Chem 1968;11:169\u201371.","DOI":"10.1021\/jm00307a601"},{"key":"2022011514475694109_j_cclm-2012-0519_ref_038","doi-asserted-by":"crossref","unstructured":"Porter J, O\u2019Loan N, Bell B, Mahoney J, McGarrity M, McConnell RI, et al. Development of an evidence biochip array kit for the multiplex screening of more than 20 anthelmintic drugs. Anal Bioannal Chem 2012;403:3051\u20136.http:\/\/gateway.webofknowledge.com\/gateway\/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000305519400028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3","DOI":"10.1007\/s00216-012-5995-6"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2012-0519\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2012-0519\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T20:01:57Z","timestamp":1642276917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2012-0519\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,11,8]]},"published-print":{"date-parts":[[2013,1,1]]}},"alternative-id":["10.1515\/cclm-2012-0519"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2012-0519","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11,8]]}}}